{"id":39501,"date":"2026-05-14T03:07:21","date_gmt":"2026-05-14T03:07:21","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=39501"},"modified":"2026-05-14T04:54:17","modified_gmt":"2026-05-14T04:54:17","slug":"rivermark-medical-raises-20-million-series-d-for-bph-flostent-system","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/rivermark-medical-raises-20-million-series-d-for-bph-flostent-system\/","title":{"rendered":"Rivermark Medical Raises $20 Million Series D for BPH FloStent System"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/rivermark-medical\/\" target=\"_blank\" rel=\"noreferrer noopener\">Rivermark Medical<\/a>, a urology-focused medical device company based in Milwaukee, has closed a $20 million Series D financing round led by <a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/andera-partners\/\" target=\"_blank\" rel=\"noreferrer noopener\">Andera Partners<\/a>, with participation from existing investors and an unnamed strategic investor. The proceeds will be used to support the company&#8217;s ongoing RAPID III pivotal clinical trial, achieve regulatory approval in the United States, and prepare for the commercial launch of its flagship product, the FloStent System.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FloStent is designed as a non-surgical, fully reversible, first-line device therapy for men with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The device can be delivered in an outpatient setting during a routine cystoscopy using standard urological tools and can be retrieved or adjusted after implantation, preserving future treatment options for patients. By combining an office-based workflow with a tissue-preserving approach, Rivermark aims to make FloStent a widely available BPH therapy. The Series D follows positive multicenter outcomes from the prior RAPID II study, in which the FloStent demonstrated rapid recovery and a durable treatment effect through 24 months of follow-up.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe class=\"lazyload\" data-src=\"https:\/\/www.youtube.com\/embed\/LTJV_chHaxQ?feature=oembed\" title=\"Dr. Adam Kadlec Interview\" width=\"800\" height=\"450\"  frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Adam Kadlec, MD, CEO and co-founder of Rivermark Medical, stated that the company is working to provide a simple, non-surgical, reversible option to men seeking BPH treatment. &#8220;Andera&#8217;s support strengthens our ability to execute on RAPID III and prepare FloStent for a successful commercial launch,&#8221; he said.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aneta Sottil, Partner at Andera Partners, noted that BPH remains a significant unmet need, with many patients unsure how to navigate the current treatment pathway. &#8220;FloStent&#8217;s very smart yet simple approach positions it as a compelling option for patients,&#8221; she said. &#8220;We are excited to support the company as they advance FloStent toward FDA approval and widespread adoption.&#8221; In conjunction with the financing, Sottil has joined Rivermark Medical&#8217;s board of directors.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rivermark Medical has closed a $20 million Series D financing led by Andera Partners to support the RAPID III pivotal trial and US regulatory approval of its non-surgical FloStent System for benign prostatic hyperplasia (BPH).<\/p>\n","protected":false},"author":2,"featured_media":39502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[7,488,681,10],"tags":[594],"class_list":["post-39501","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-breaking-news","category-care-therapy","category-strategic-development","tag-financing"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/39501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/comments?post=39501"}],"version-history":[{"count":5,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/39501\/revisions"}],"predecessor-version":[{"id":39507,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/39501\/revisions\/39507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media\/39502"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media?parent=39501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/categories?post=39501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/tags?post=39501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}